Celastrol and an EGCG pro-drug exhibit potent chemosensitizing activity in human leukemia cells

International Journal of Molecular Medicine

Volumn 25, Issue 3, 2010, Pages 465-470

  Davenport, Andrew ^a   Frezza, Michael ^a   Shen, Min ^a   Ge, Yubin ^a   Huo, Congde ^b   Chan, Tak Hang ^b   Dou, Q Ping ^a  

^a KARMANOS CANCER INSTITUTE   (United States)

^b MCGILL UNIVERSITY   (Canada)

Author keywords

Apoptosis; Chemosensitizing; Chemotherapy; Leukemia; Natural products; Pro drug

Indexed keywords

BCR ABL PROTEIN; CASPASE 3; CELASTROL; CYTARABINE; DAUNORUBICIN; EPIGALLOCATECHIN GALLATE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PRODRUG;

APOPTOSIS; ARTICLE; BIOLOGICAL ACTIVITY; CANCER CELL DESTRUCTION; CELL KILLING; CELL STRAIN K 562; CONTROLLED STUDY; DRUG POTENCY; DRUG SENSITIVITY; ENZYME ACTIVATION; HUMAN; HUMAN CELL; LEUKEMIA CELL; PRIORITY JOURNAL; PROTEIN CLEAVAGE;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CATECHIN; CELL LINE, TUMOR; CYTARABINE; DAUNORUBICIN; FUSION PROTEINS, BCR-ABL; HUMANS; LEUKEMIA; MOLECULAR STRUCTURE; PLANT EXTRACTS; PRODRUGS; TRITERPENES;

EID: 76949108486     PISSN: 11073756     EISSN: 1791244X     Source Type: Journal    
DOI: 10.3892/ijmm_00000366     Document Type: Article

References (27)

1. Tallman MS, Gilliland DG and Rowe JM: Drug therapy for acute myeloid leukemia. Blood 106: 1154-1163, 2005.
2. Huang RS, Duan S, Kistner EO, Bleibel WK, Delaney SM, Fackenthal DL, Das S and Dolan ME: Genetic variants contributing to daunorubicin-induced cytotoxicity. Cancer Res 68: 3161-3168, 2008.
3. Liu J, Mi Y, Fu M, Yu W, Wang Y, Lin D, Bian S and Wang J: Intensive induction chemotherapy with regimen containing intermediate dose cytarabine in the treatment of de novo acute myeloid leukemia. Am J Hematol 84: 422-427, 2009.
4. Hubeek I, Stam RW, Peters GJ, Broekhuizen R, Meijerink JP, van Wering ER, Gibson BE, Creutzig U, Zwaan CM, Cloos J, Kuik DJ, Pieteres R and Kaspers GJ: The human equilibrative nucleoside transporter 1 mediates in vitro cytarabine sensitivity in childhood acute myeloid leukemia. Br J Cancer 93: 1388-1394, 2005.
5. Karbasian-Esfahani M, Wiernik PH, Novik Y, Paietta E and Dutcher JP: Indarubicin and standard dose cytosine arabinoside in adults with recurrent and refractory acute lymphocytic leukemia. Cancer 101: 1414-1419, 2004.
6. Fujiki H, Suganuma M, Imai K and Nakachi K: Green tea: cancer preventative beverage and/or drug. Cancer Lett 188: 9-13, 2002.
7. Inoue M, Tajima K, Hirose K, et al: Tea and coffee consumption and the risk of digestive tract cancers: data from a comparative case-referent study in Japan. Cancer Causes Control 9: 209-216, 1998.
8. Shanafelt TD, Lee YK, Call TG, et al: Clinical effects of oral green tea extract in four patients with low grade B-cell malignancies. Leuk Res 30: 707-712, 2006.
9. Sartippour MR, Heber D, Ma J, Lu Q, Go VL and Nguyen M: Green tea and its cathechins inhibit breast cancer xenografts. Nutr Cancer 40: 149-156, 2001.
10. Nam S, Smith DM and Dou QP: Inhibition of proteasome activity in vitro and in vivo by ester bond-containing tea polyphenols. J Biol Chem 276: 13322-13330, 2001.
11. Lam WH, Kazi A, Kuhn DJ, et al: A potential prodrug for a green tea polyphenol proteasome inhibitor: evaluation of the peracetate ester of (-) epigallocatechin gallate [(-)-EGCG]: Bioorg Med Chem 12: 5587-5593, 2004.
12. Setty AR and Sigal LH: Herbal medications commonly used in the practice of rheumatology: mechanisms of action, efficacy, and side effects. Semin Arthritis Rheum 34: 773-784, 2005.
13. Tao X, Younger J, Fan FZ, Wang B and Lipsky PE. Benefit of an extract of Tripterygium wilfordii Hook F in patients with rheumatoid arthritis: a double-blind, placebo-controlled study. Arthritis Rheum 46: 735-743, 2002.
14. Pinna GF, Fiorucci M, Reimund JM, Taquet N, Arondel Y and Muller CD: Celastrol inhibits pro-inflammatory cytokine secretion in Crohn's disease biopsies. Biochem Biophys Res Commun 322: 778-786, 2004.
15. Chang FR, Hayashi K, Chen LH, Liaw CC, Bastow KF, Nakanishi Y, Nozaki H, Cragg GM, Wu YC and Lee KH: Antitumor agents. 228. five new agarofurans, Reissantins A-E, and cytotoxic principles from Reissantia buchananii. J Nat Prod 66: 1416-1420, 2003.
16. Nagase M, Oto J, Sugiyama S, Yube K, Takaishi Y and Sakato N: Apoptosis induction in HL-60 cells and inhibition of topoisomerase II by triterpene celastrol. Biosci Biotechnol Biochem 67: 1883-1887, 2003.
17. Yang H, Chen D, Cui QC, Yuan X and Dou QP: Celastrol, a triterpene extracted from the Chinese 'Thunder of God Vine' is a potent proteasome inhibitior and suppresses human prostate cancer growth in nude mice. Cancer Res 66: 4758-4765, 2006.
18. Wan SB, Dou QP and Chan TH: Regiospecific and enantioselective synthesis of methylated metabolites of tea catechins: Tetrahedron 62: 5897-5904, 2006.
19. An B and Dou QP: Cleavage of retinoblastoma protein during apoptosis: an interleukin 1β-converting enzyme-like protease as candidate. Cancer Res 56: 438-432, 1996.
20. An B, Goldfarb RH, Siman R and Dou QP: Novel dipeptidyl proteasome inhibitiors overcome Bcl-2 protective function and selectively accumulate the cyclin-dependent kinase inhibitor p27 and induce apoptosis in transformed, but not normal, human fibroblasts: Cell Death Differ 5: 1062-1075, 1998.
21. Landis-Piwowar KR, Huo C, Chen D, Milacic V, Shi G, Chan TH and Dou QP: A novel prodrug of the green tea polyphenol(-)-epigallocatechin-3-gallate as a potential anticancer agent. Cancer Res 67: 4303-4310, 2007.
22. Nicholson DW and Thornberry NA: Apoptosis. Life and death decisions. Science 299: 214-215, 2003.
23. Savona M and Talpaz M: Getting to the stem of chronic myeloid leukemia. Nature Rev 8: 341-350, 2008.
24. Sarkar FH and Li YW: Harnessing the fruits of nature for the development of multi-targeted cancer therapeutics. Cancer Treat Rev 35: 567-607, 2009.
25. Sarkar FH and Li YW: Targeting multiple signal pathways by chemopreventative agents for cancer prevention and therapy. Acta Pharmacol Sin 28: 1305-1315, 2007.
26. Dhillon N, Aggarwal BB, Newman RA, et al: Phase II trial of curcumin in patients with advanced pancreatic cancer. Clin Cancer Res 14: 4491-4499, 2008.
27. Usuki K, Lijima K, Lki S and Urabe A: Cytogenetic relapse after cessation of imatinib therapy. Leuk Res 29: 237-238, 2005.